CYP19A1 and breast cancer: The American Society of Clinical Oncology Technology Assessment Panel recommends that 5 years of tamoxifen alone is no longer the best adjuvant treatment for postmenopausal patients with hormone-sensitive early breast cancer, and that optimal treatment should include an aromatase inhibitor to reduce the risk of tumor recurrence [10].